A director at Iberdrola S.A. bought 3,500 shares at 15.710EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Kinepolis: Box office doubles in US/Canada, flat attendance in France. KPN: VodafoneZiggo goes for accelerated DOCSIS 4.0 roll out, answering infra question. Lotus Bakeries: CEO expects US$100m in sales in India by the end of the decade. Philips: 1Q25 results – Guidance lowered on tariffs. PostNL: 1Q25 in line with consensus; FY25 outlook reiterated
Rdos. 1T'25 vs 1T'24: Ventas: 4.097 M euros (-1,0% vs -2,0% BS(e) y -2,9% consenso); EBITA Ajustado: 354,0 M euros (-8,8% vs -17,3% BS(e) y -20,4% consenso); BDI: 72,0 M euros (-998,0 M euros en 1T'24 vs 33,0 M euros BS(e) y 19,0 M euros consenso).
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAF, IBERDROLA, INDRA, SANTANDER. EUROPA: PHILIPS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’25 que se publicarán en España y Europa en los próximos días. El Ibex recupera los 13.500 puntos Las bolsas de Europa se decantaron en su mayoría por las subidas a excepción del CAC, que terminó en negativo...
NEWS SUMMARY: CAF, IBERDROLA, INDRA, SANTANDER. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’25 results to be released over the coming days in Spain. IBEX back above 13,500 European stock markets mostly rose, except the CAC which ended in the red and the Eurostoxx 50, which was flat. In the STOXX 600, most sectors posted gains (14/20), led by Insurance and Real Estate, w...
Philips delivers on Q1 results, with ongoing order intake growth May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.